글로벌 후천성 면역 결핍 증후군(AIDS) 치료 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

후천성 면역 결핍 증후군(AIDS) 치료 시장 분석

시장은 HIV 발병률 증가와 항레트로바이러스 요법(ART)의 발전으로 인해 상당한 성장을 경험하고 있습니다. NRTI, NNRTI, 인테그라제 억제제를 포함한 이러한 요법은 바이러스를 관리하고 환자 건강 결과를 개선하는 데 필수적입니다. 최근 개발은 환자에게 더 편리한 치료 옵션을 제공하고 준수를 강화하는 Cabenuva와 같은 장기 작용 주사 제형의 도입을 강조합니다. 또한 혁신적인 백신과 기능적 치료법을 포함한 예방 전략에 대한 지속적인 연구가 추진력을 얻고 있습니다. 시장은 또한 특히 자원이 제한된 환경에서 저렴한 치료법 에 대한 접근성을 높이기 위한 노력을 목격하고 있으며 , 따라서 치료의 도달 범위를 확대하고 있습니다. 혁신과 접근성에 중점을 두고 있는 AIDS 치료 시장은 HIV/AIDS의 영향을 받는 사람들의 삶의 질을 개선하는 것을 목표로 지속적인 확장을 위한 좋은 위치에 있습니다.

후천성면역결핍증후군(AIDS) 치료제 시장 규모

글로벌 후천성 면역 결핍 증후군(AIDS) 치료 시장 규모는 2023년에 340억 4천만 달러로 평가되었으며, 2031년까지 458억 8천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 3.80%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

후천성면역결핍증후군(AIDS) 치료 시장 동향

“ 장기간 작용하는 주사제의 부상”

시장은 혁신과 환자 중심 치료에 초점을 맞춘 혁신적인 추세를 목격하고 있습니다. 주목할 만한 추세 중 하나는 환자의 준수와 편의성을 강화하는 장기 작용 주사형 항레트로바이러스 요법의 채택이 증가하고 있다는 것입니다. 매월 또는 2개월마다 투여하는 주사형 치료제인 Cabenuva와 같은 혁신은 매일 복용하는 경구 약물에 대한 대안을 제공하여 HIV 감염자의 삶의 질을 크게 개선합니다. 또한 효능을 최적화하고 내성 가능성을 줄이기 위해 복합 요법의 발전이 모색되고 있습니다. 시장은 또한 유전적 및 바이러스적 특성에 따라 개별 환자 프로필에 맞게 치료를 조정하는 개인화 의학으로 전환되고 있습니다. 백신 및 기능적 치료법과 같은 예방 조치에 대한 지속적인 연구와 함께 AIDS 치료 환경은 건강 결과를 개선하고 궁극적으로 HIV/AIDS의 세계적 부담을 줄이는 것을 목표로 빠르게 진화하고 있습니다.

보고 범위 및 후천성 면역 결핍 증후군(AIDS) 치료 시장 세분화

Acquired Immunodeficiency Syndrome (AIDS) Treatment Market Definition

Acquired Immunodeficiency Syndrome (AIDS) treatment refers to the medical care and interventions aimed at managing and controlling the progression of HIV infection, which leads to AIDS. This treatment primarily involves the use of antiretroviral therapy (ART), which consists of a combination of medications designed to suppress the replication of the HIV virus, improve immune function, and enhance the quality of life for individuals living with HIV/AIDS. The goal of AIDS treatment is to reduce viral load to undetectable levels, thereby preventing the progression to AIDS and decreasing the risk of transmission to others. Treatment may also include preventive measures, management of opportunistic infections, and regular monitoring of immune health.

Acquired Immunodeficiency Syndrome (AIDS) Treatment Market Dynamics

Drivers

• Increasing Rates of HIV Infections

The increasing rates of HIV infections globally serve as a critical market driver necessitating enhanced treatment options in the Acquired Immunodeficiency Syndrome (AIDS) treatment market. According to the World Health Organization (WHO), approximately 39.9 million people were living with HIV at the end of 2023, highlighting the urgent need for effective management strategies. This growing prevalence underscores the importance of developing and expanding access to antiretroviral therapy (ART), which is essential for suppressing the virus and improving the quality of life for those affected. Additionally, the rise in new infections, particularly among vulnerable populations, amplifies the demand for innovative treatment solutions. As healthcare systems adapt to these challenges, increased investment in research and development of novel therapies becomes crucial to effectively address the evolving landscape of HIV/AIDS management, driving market growth in this sector.

• Integration of Telehealth and Digital Health Technologies

Innovations in antiretroviral therapy (ART) are significantly enhancing treatment efficacy and patient adherence in managing HIV/AIDS. The development of long-acting injectable formulations, such as Cabenuva, allows patients to receive treatment less frequently—monthly or bimonthly—compared to daily oral medications. This convenience reduces the burden of adherence, particularly for those struggling with daily pill regimens. Additionally, combination therapies that integrate multiple classes of antiretroviral agents streamline treatment regimens, minimize the risk of drug resistance, and improve overall effectiveness. These advancements lead to better viral suppression and enhance patients' quality of life by providing more manageable treatment options, ultimately driving better health outcomes in the HIV-positive population.

Opportunities

• Development of Novel Antiretroviral Therapies

The development of novel antiretroviral therapies is a pivotal factor in expanding the Acquired Immunodeficiency Syndrome (AIDS) treatment market. Innovations such as long-acting injectables provide patients with a more convenient alternative to daily oral medications, allowing treatment administration on a monthly or bimonthly basis. This approach significantly enhances treatment adherence, particularly among individuals who find daily pills challenging to manage. Additionally, advancements in gene therapies aim to provide more effective and durable solutions for HIV management, potentially offering a functional cure for some patients. By attracting new patient populations and improving overall treatment experiences, these cutting-edge therapies are instrumental in creating opportunities for market growth and transforming HIV care.

• Rise of Telehealth Services

The rise of telehealth services is revolutionizing the management of HIV/AIDS by enhancing patient monitoring and engagement. With telehealth, healthcare providers can offer remote consultations, allowing patients to receive care from the comfort of their homes. This accessibility is particularly beneficial for individuals in rural or underserved areas who may face barriers in accessing traditional healthcare facilities. Telehealth also facilitates continuous patient engagement through regular virtual check-ins, medication reminders, and support for adherence to treatment regimens. Additionally, these services enable healthcare providers to closely monitor patient progress and adjust treatment plans in real time, ensuring optimal care. As a result, telehealth is improving patient outcomes and expanding the reach of healthcare services in the AIDS treatment market.

Restraints/Challenges

• Societal Stigma in HIV/AIDS Treatment

Societal stigma surrounding HIV/AIDS presents a significant challenge in the Acquired Immunodeficiency Syndrome (AIDS) treatment market, deterring individuals from seeking testing and treatment. Negative perceptions and discrimination can lead to feelings of shame and fear, causing many to avoid healthcare services. This reluctance often results in late diagnoses, where individuals may only seek medical help when their health has significantly deteriorated, leading to poorer health outcomes and increased transmission rates. Furthermore, stigma can extend to healthcare providers, who may unconsciously harbor biases that impact the quality of care offered to patients with HIV/AIDS.

•  High Treatment Costs

The cost of antiretroviral therapy (ART) poses a significant challenge in the fight against HIV/AIDS, particularly for patients lacking adequate insurance coverage. While ART is crucial for managing the virus and preventing disease progression, its high cost can be a major barrier, especially for those in low-income communities or countries with limited healthcare resources. For many individuals, the financial burden of continuous treatment can lead to difficult choices between healthcare and other essential needs, such as housing or food. This limitation on access to essential treatments affects individual health outcomes and exacerbates public health issues, increasing the risk of virus transmission within communities.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Acquired Immunodeficiency Syndrome (AIDS) Treatment Market Scope

The market is segmented on the basis of type, mechanism of action, drugs, route of administration, distribution channel, and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• HIV-1
• HIV-2

Mechanism of Action

• Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
• Non-Nucleoside Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Fusion Inhibitors
• CCR5 Antagonist
• Integrase Inhibitors
• Monoclonal Antibody
• Others

Drugs

• Abacavir
• Delavirdine
• Atazanavir
• Enfuvirtide
• Maraviroc
• Dolutegravir
• Ibalizumab
• Others

Route of Administration

• Oral
• Intravenous
• Others

Distribution Channel

• Direct
• Online Pharmacy
• Retailers
• Others

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

 Acquired Immunodeficiency Syndrome (AIDS) Treatment Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, mechanism of action, drugs, route of administration, distribution channel, and end-users as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific region leads the acquired immunodeficiency syndrome (AIDS) treatment market, primarily due to its vast population and increasing prevalence of HIV. This demographic trend creates a substantial demand for effective treatment options and healthcare services. Furthermore, rising awareness and initiatives to combat HIV/AIDS contribute to the region's market dominance. As healthcare infrastructure improves, the ability to address the needs of those affected by the virus continues to strengthen in this dynamic market.

North America is anticipated to experience growth in the acquired immunodeficiency syndrome (AIDS) treatment market, driven by the presence of prominent industry players. The region's substantial healthcare expenditure further supports advancements in treatment options and technologies. Additionally, a well-established healthcare infrastructure facilitates the delivery of high-quality services to patients. These factors collectively contribute to North America's robust position in the AIDS treatment market during the forecast period.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Acquired Immunodeficiency Syndrome (AIDS) Treatment Market Share

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 운영되는 후천성 면역 결핍 증후군(AIDS) 치료 시장 리더는 다음과 같습니다.

• 애벗(미국)
• 길리드 사이언스 주식회사(미국)
• GSK plc (영국)
• 브리스톨-마이어스 스퀴브 회사(미국)
• Viatris Inc. (미국)
• 존슨앤존슨 서비스 주식회사(미국)
• 머크앤코(미국)
• 베링거인겔하임인터내셔널(독일)
• 시플라(인도)
• 홀로직 주식회사(미국)
• 파이저 주식회사(미국)
• 포인트케어(미국)
• 리간드 파마슈티컬스 인코퍼레이티드(미국)
• 센타우르 파마슈티컬스(인도)
• 샌가모 테라퓨틱스(미국)
• 이노비오제약(미국)
• 트로가르조(대만)

후천성 면역 결핍 증후군(AIDS) 치료 시장의 최신 동향

• 2021년, 식품의약국(FDA)은 바이러스 억제의 입증된 병력이 있는 개인을 위한 새로운 항레트로바이러스 요법(ART) 요법으로 카보테그라비르와 릴피비린을 승인했습니다. 이 혁신적인 치료법은 HIV를 효과적으로 관리한 환자에게 대안을 제공하여 덜 빈번한 투여 옵션을 허용합니다. 이 두 가지 약물의 조합은 환자의 준수를 강화하고 전반적인 치료 결과를 개선하는 것을 목표로 합니다. 이 승인을 통해 의료 서비스 제공자는 HIV를 관리하는 데 더 효과적인 전략을 사용할 수 있게 되어 바이러스에 감염된 사람들의 치료 표준을 발전시킬 수 있습니다.

SKU-50471